CoChat

Nachweis von SLA/LP-Autoantikörpern bei Patienten mit primär biliärer Zirrhose als Marker für eine sekundäre autoimmune Hepatitis (Overlapsyndrom)

Kanzler, S, Bozkurt, S, Herkel, J, Galle, P, Dienes, H, Lohse, A · 2001 · DMW - Deutsche Medizinische Wochenschrift

The DOI matches its Crossref record, with a small difference in title or year.

Abstract

Hintergrund und Fragestellung: Ziel der vorliegenden Studie war es, zu untersuchen, inwieweit der Nachweis von anti-SLA/LP-Autoantikörper bei Patienten mit primär biliärer Zirrhose einen Hinweis auf eine hepatitische Verlaufsform bzw. ein Autoimmune Hepatitis/Primär biliäre Zirrhose(AIH/PBC)-Overlapsyndrom gibt. Patienten und Methodik: Aus 233 konsekutiven PBC-Patienten, die zwischen Oktober 1980 und April 2000 betreut worden waren, wurden die Daten anti-SLA/LP-positiver Patienten ausgewertet und mit Verläufen von Patienten mit anti-SLA/LP-negativem AIH/PBC-Overlapsyndrom sowie mit klassischer Verlaufsform einer PBC und AIH verglichen. Ergebnisse: Insgesamt konnten neun PBC-Patienten (sechs Frauen/drei Männer) oder 3,9 % des Patientenkollektivs identifiziert werden, die anti-SLA/LP-Autoantikörper aufwiesen. Diese waren bei Diagnosestellung etwas jünger als anti-SLA/LP-negative PBC-Patienten (49,9 vs. 53,2 Jahre). Transaminasen und γ-Globuline lagen bei den anti-SLA/LP-positiven PBC-Patienten deutlich höher als bei anti-SLA/LP-negativen PBC-Patienten (Mittelwert : 235 vs. 55 IU/l und 27,6 vs. 19,5 g/l). Anti-SLA/LP-positive Patienten wiesen signifikant häufiger einen für die AIH typischen HLA-Typ auf (B8; DR3; DR4). Eine immunsuppressive Therapie führte zu einer deutlichen Abnahme der entzündlichen Aktivität und der laborchemischen Cholestase. Nach Reduktion oder Absetzen der Immunsuppression waren Rezidive häufig. Folgerung: Der Nachweis von anti-SLA/LP-Antikörpern bei PBC-Patienten ist hochspezifisch für das Vorliegen eines AIH/PBC-Overlapsyndrom. Diese Patienten sprechen gut auf eine immunsuppressive Therapie an. Das Autoantikörperprofil und die Immungenetik könnten in Zukunft weiterhelfen, PBC-Patienten zu identifizieren, die besonders von einer immunsuppressiven Therapie profitieren. Presence of SLA/LP-autoantibodies in patients with primary biliary cirrhosis as a marker for secondary autoimmune hepatitis (overlap syndome) Background and objective: The aim of this study was to evaluate whether the presence of SLA/LP-autoantibodies in PBC-patients gives evidence for a secondary AIH, also called AIH/PBC-overlap-syndrome. Patients and methods: Out of 233 consecutive patients with PBC who had been followed between October 1980 and April 2000, we evaluated the data of anti-SLA/LP-positive patients and compared them to patients with an anti-SLA/LP-negative AIH/PBC overlap syndrome as well as to patients with a classical course of AIH and PBC. Results: In total we could identify nine PBC patients with anti-SLA/LP antibodies (six women/three men) or 3.9 % of the study population. Anti-SLA/LP-positive PBC patients were slightly younger at diagnosis in comparison to anti-SLA/LP-negative PBC-patients (49,9 vs. 53.2 years). Transaminases and γ-globulins were significantly higher in anti-SLA/LP-positive PBC-patients in comparison to anti-SLA/LP-negative PBC-patients (mean: 235 vs. 55 IU/l and 27.6 vs. 19.5 g/l). Anti-SLA/LP-positive patients significantly more frequently had an HLA-type that is characteristic for AIH (B8; DR3; DR4). Immunosuppressive therapy reduced inflammatory activity and cholestasis significantly. Relapses were frequent after reduction or discontinuation of immunosuppressive therapy. Conclusion: The presence of SLA/LP autoantibodies in PBC patients has a high specificity for a secondary AIH (AIH/PBC overlap syndrome). These patients have a good response to immunosuppressive therapy. The autoantibody profile and immunogenetics may help in future to identify PBC patients that benefit most from immunosuppressive therapy. 1 Die AIH- und PBC-Patienten, mit den die hier beschriebenen anti-SLA/LP-positiven PBC-Patienten verglichen wurden, entstammen aus der Veröffentlichung: Lohse et al.; Hepatology 1999; 29: 1078-1084.

Overview

Integrity signals

Registry

Crossref · 10.1055/s-2001-12906

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Still being checked.

Cited by

Metadata

Authors
Kanzler, S., Bozkurt, S., Herkel, J., Galle, P., Dienes, H., & Lohse, A.
Affiliations
  • Johannes Gutenberg University Mainz (DE)
  • University of Cologne (DE)
Venue
DMW - Deutsche Medizinische Wochenschrift
Published
2001-12-31
Volume
126
Issue
16
Pages
450-456
ISSN
  • 0012-0472 (ISSN-L)
  • 1439-4413
OpenAlex
W2410168206
Cited by
33
References
0
Citations by year
2026: 2 · 2025: 1 · 2019: 2 · 2018: 2 · 2017: 2 · 2016: 1 · 2014: 1 · 2013: 1
FWCI
1.24
Type
journal article
Language
de
Open access
closed
Locations
  • DMW - Deutsche Medizinische Wochenschrift (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
Keywords
primary biliary cirrhosis, autoimmune hepatitis, HLA class II association, HLA-B8, HLA-DR3, HLA-DR4, immunosuppressive therapy, relapse, cholestasis, serological diagnosis, age at diagnosis, transaminases
MeSH terms
Adult, Aged, Transaminases, Autoantibodies, Biopsy, Data Interpretation, Statistical, Clinical Enzyme Tests, Enzyme-Linked Immunosorbent Assay, Female, Fluorescent Antibody Technique, Follow-Up Studies, gamma-Globulins, Humans, Immunosuppressive Agents, Liver, Liver Cirrhosis, Biliary, Male, Middle Aged, Time Factors, Blotting, Western, Hepatitis, Autoimmune

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.